The merger is a transformative reverse acquisition that will give Ambros a public listing and capital via the PIPE. Werewolf holders face massive dilution (to ~6.4% of the combined entity) but receive CVRs tied to legacy asset sales. The key binary event is the December 17 stockholder vote; failure to approve the required proposals would terminate the deal and likely force Werewolf into dissolution or another strategic transaction.
Drug in focus
HOWL drug pipeline →neridronate
● Neutral Named in this S-4/A- Impact
- Phase
- Phase 3
- Time to market
- Topline Phase 3 results expected in 2028, NDA submission thereafter, potential FDA approval likely no earlier than 2029 if the trial succeeds.
- Next catalyst
- None dated
What to watchWatch for the timing and outcome of the CRPS-RISE interim analysis, which could allow the trial to stop early for efficacy or futility. The merger with Ambros is still being finalized (S-4/A filed November 10, 2026), and current HOWL shareholders face massive dilution, owning roughly 7% of the combined entity. The $150 million PIPE is expected to fund the company through topline results in 2028 and into 2029, reducing near-term financing risk.
- ▼ WTX-124 3/10 unknown — not confirmed this session (SecBot's FDA/ClinicalTrials.gov ingestion holds no WTX-124 records; external web s
- ● WTX-330 2/10 Unknown/unverified — no Phase 2/3 industry-sponsored records for WTX-330 exist in SecBot's ingested ClinicalTrials.gov d
- All HOWL drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $0.9889entry
- T+1 · 5d ago −0.90%α −0.55% · $0.9800
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Werewolf Therapeutics filed Amendment No. 2 to its S-4 registration statement for the proposed reverse merger with Ambros Therapeutics. Under the merger agreement, Ambros (valued at $500M) will become a wholly owned subsidiary of Werewolf, which will rename to Ambros Therapeutics. A concurrent $150M PIPE financing will close alongside the merger. Pre-merger Werewolf holders will own approximately 6.4% of the combined company, Ambros holders approximately 72.0%, and PIPE investors approximately 21.6%. The combined company will focus on Ambros' lead candidate neridronate for CRPS-1. Werewolf stockholders must approve several proposals at a December 17, 2026 special meeting for the merger to close, expected by Q1 2027.
Key Facts
- Ambros equity value set at $500.0 million, Werewolf at $47.5 million
- Concurrent PIPE financing of $150.0 million with minimum $100.0 million condition
- Estimated exchange ratio: 10.7623 Werewolf shares per Ambros share
- Post-merger ownership: Werewolf holders 6.4%, Ambros holders 72.0%, PIPE investors 21.6%
- Combined company to trade on Nasdaq under symbol AMBX
- Werewolf stockholders to receive CVRs for legacy WTX-124 and WTX-330 programs
- Special meeting scheduled for December 17, 2026; closing expected Q1 2027
- Werewolf had $22.0M cash as of June 30, 2026 and accumulated deficit of $485.3M
- Ambros had $103.2M cash as of June 30, 2026 and accumulated deficit of $60.8M
- Werewolf received Nasdaq deficiency notice for minimum bid price non-compliance
Financial Impact
Ambros valued at $500M equity; $150M PIPE; combined company cash runway into first half of 2029
Risk Factors
- Stockholder approval of required proposals is not guaranteed; failure would terminate the merger
- Nasdaq listing condition for combined company shares may not be satisfied
- Werewolf faces going concern risk if merger fails; would need additional funding or dissolution
- Ambros' lead candidate neridronate has prior Phase 3 failures by Grnenthal; CRPS-RISE trial may not succeed
- Massive dilution for existing Werewolf holders (to 6.4% of combined company)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001140361-26-043046 |
| Document: ny20081588x4_ex107.htm | 0001140361-26-043046 |
| Document: ny20081588x4_ex5-1.htm | 0001140361-26-043046 |
| Document: ny20081588x4_ex99-1.htm | 0001140361-26-043046 |
| Document: ny20081588x4_ex23-2.htm | 0001140361-26-043046 |
| Document: ny20081588x4_ex23-1.htm | 0001140361-26-043046 |
| Document: 0001140361-26-043046-index-headers.html | 0001140361-26-043046 |
| Document: 0001140361-26-043046-index.html | 0001140361-26-043046 |
| Document: 0001140361-26-043046.txt | 0001140361-26-043046 |
Track record
31 reports on HOWL
12 of 16 bullish or bearish reports moved the stock their way by T+5. Best: +51.32% at T+60 after the Apr 27, 2026 report. 13 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.9500 Now $0.9910 +4.32% settles Nov 23
- Nov 13, 20264d ago EFFECT Neutral 4/10 Entry $0.9803 Now $0.9910 +1.09% settles Nov 20
- Nov 10, 20266d ago S-4/A Neutral 5/10 Viewing Entry $0.9889 Now $0.9910 +0.21% settles Nov 18
- Nov 9, 20267d ago 425 Neutral 5/10 Entry $0.9700 Now $0.9910 +2.16% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Oct 26, 202621d ago S-4/A Bearish 5/10 Entry $1.04 to $1.07 Now $0.9910 +4.71% ▼ −2.88% −4.87% vs SPY
- Sep 22, 20267w ago S-4 Bearish 7/10 Entry $0.9894 to $0.9223 Now $0.9910 −0.16% ▲ +6.78% +6.11% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 3/10 Entry $0.9800 to $0.9300 Now $0.9910 +1.12% ▼ −5.10% −4.08% vs SPY
- Aug 21, 202612w ago 425 Bullish 7/10 Entry $0.8740 to $0.9433 Now $0.9910 +13.39% ▲ +7.93% +7.46% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers